Peter Mu, PhD, MBA, President and CEO
Dr. Mu has more than 15 years of industry experience in new drug development at global contract research organizations and pharmaceutical companies, and held management positions at WuXi AppTec, Lexicon Pharmaceuticals, and Covance. He has led and contributed to various pharmaceutical development programs, ranging from IND to successful NDA. He has licensed technologies from various organizations and raised federal, state, and venture financing. Dr. Mu received a PhD in Toxicology at North Carolina State University and an MBA in Life Sciences at the Johns Hopkins University.
Paul Yang, MD, PhD, Clinical Advisor
Dr. Yang is an assistant professor in ophthalmic genetics and immunology at the Casey Eye Institute, Oregon Health & Science University. He is a PI and sub-I on numerous gene therapy and neuroprotection clinical trials for inherited retinal degenerations. He was funded by the Foundation Fighting Blindness (FFB) Clinical Research Fellowship Award, FFB Career Development Award, and NIH. He received his MD/PhD at Dartmouth Medical School and completed his residency and fellowship at the Moran Eye Center and the Massachusetts Eye Research and Surgery Institution.
Gary G. Altman, PhD, Board Member
Dr. Altman is an investor, entrepreneur and leader of large and small scientific organizations. His experiences include senior management positions at Beckman Coulter, Sequoia Pharmaceuticals, and Sandstone Diagnostics as well as advisor to GE Healthcare, Terumo-CaridianBCT and GenVec among others. He earned a PhD in biochemistry/virology and held an NSF Post-Doctoral Fellowship in the BioPhysics and McArdle Laboratories at the University of Wisconsin, Madison.